A) Reticulocyte Hemoglobin (RET-HE) 1. Renal disease application Anemia in patients with CKD is due to many factors. Erythropoietin and iron homeostasis are impaired as a result of a complex chain of events, including the relative deficiency of erythropoietin, chronic inflammation, blood loss, decreased iron absorption and utilization, exogenous iron and erythropoietin acquisition via biologically unregulated mechanisms (blood transfusions and medicinal erythropoietin and iron administration). Recombinant human erythropoietin (rHuEpo) has been available for treatment of renal disease anemia since 1989.
However, rHuEpo therapy results in iron deficiency due to insufficient iron stores for the accelerated erythropoiesis. Iron deficiency is the main cause of suboptimal response to erythropoietin in dialysis patients. Maintenance iron supplementation is required to successfully treat…
